^
Association details:
| Biomarker: | MSH2 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) + oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy
Published date:
10/01/2018
Excerpt:
Twenty of the 49 patients received induction chemotherapy with 5FU and oxaliplatin...28% (n = 5) of patients demonstrated progressive disease while on therapy. The majority of these cases, 82% (41/50) harbored germline mutations in the MMR genes and the observed prevalence of germline MSH2 and MSH6 mutations was significantly higher in the rectal (n = 41)...Patients with MMR-D rectal tumors appear to have a high chance of disease progression on induction chemotherapy.
DOI:
10.1093/annonc/mdy281.047
